Newsfeeds - Spark Newswire

4 minute read

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

Today, 3:51 AM

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

1 minute read

Earnings

A Preview Of Kala Pharmaceuticals’s Earnings

By Benzinga Insights

Today, 3:51 AM

Kala Pharmaceuticals (NASDAQ:KALA) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement. Analysts estimate that Kala Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-0.43

KALA

1 minute read

Watching Muscle Maker; Traders Circulate PennyStocks.com Article ‘Best Penny Stocks To Buy Now? 5 To Watch Before Next Week’ Mentioning Stock

By Benzinga Newsdesk

Today, 3:51 AM

https://pennystocks.com/featured/2021/11/04/best-penny-stocks-to-buy-now-5-to-watch-next-week/

GRIL

1 minute read

‘Best Penny Stocks To Buy For A Short Squeeze? 10 To Watch Today’ -Pennystocks.com; Article Mentions Voyager Therapeutics, Kala Pharma, Electrameccanica, Meta Materials, Clovis Oncology

By Benzinga Newsdesk

Today, 3:51 AM

https://pennystocks.com/featured/2021/11/01/best-penny-stocks-to-buy-short-squeeze-10-to-watch-today/

CLVS

4 minute read

46 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:51 AM

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.

AGRX

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 3:51 AM

ADMP

3 minute read

34 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 3:51 AM

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.

AGRX